Pasar al contenido principal

La información sobre este estudio está en inglés.

Si necesita ayuda en español, comuníquese con el Centro de Educación y Referencias sobre la Enfermedad de Alzheimer y las Demencias Relacionadas (ADEAR, por sus siglas en inglés) por teléfono al 800-438-4380 o envíe un correo electrónico. También puede llamar o enviar un correo electrónico al contacto del estudio (en inglés) para obtener información adicional.

Find more clinical trials

Novel Measures for Alzheimer's Disease Prevention Trials (NoMAD)

Start: February 25, 2019
End: March 31, 2023
Enrollment: 320

What Is This Study About?

This study is recruiting volunteers with no cognitive impairment to help test new assessments of cognition and everyday function. The assessments are being developed for use in Alzheimer's prevention trials. Participants will be randomly assigned to receive three assessments, either novel or established, over a one-year period.

Do I Qualify To Participate in This Study?

Minimum Age: 60 Years

Maximum Age: 85 Years

Must have:

  • English speaking
  • Mini-Mental State Examination score of 24 or greater
  • Logical Memory II score of 9 or greater for individuals with 16 or more years of education, 5 or more for individuals with 8 to 15 years of education, and 3 or greater for individuals with 0 to 7 years of education
  • Subjective memory complaints not exclusionary
  • Family member or other individual who has regular contact with the participant and can provide information during the study

Must NOT have:

  • Diagnosis of stroke or excessive risk of cardiovascular disease
  • Neurologic disease, including movement disorders, multiple sclerosis, epilepsy, and traumatic brain injury with loss of consciousness for 15 minutes or more
  • Untreated diabetes
  • Psychiatric diagnosis of schizophrenia or bipolar disorder, or current major depression as determined by a Geriatric Depression Scale score of greater than 5
  • Current alcohol or substance use disorder
  • Active treatment of cancer
  • Women who are premenopausal or are pregnant
  • Prohibited medications: antidepressants with large anticholinergic properties, including amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, isocarboxazide, lithium, maprotiline, mirtazapine, nortriptyline, tranylcypromine trimipramine, and phenelzine

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Study Contact
Terry E. Goldberg, Ph.D.
Davangere P. Devanand, M.D.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

University of Southern California
Los Angeles, CA 90033
Cynthia Munoz
University of Miami
Miami, FL 33136
Philip D. Harvey, Ph.D.
New York
The Feinstein Institute for Medical Research
Manhasset, NY 11030
Lynda Keehlisen
New York State Psychiatric Institute
New York, NY 11032
Daniel Cohen, BA

Who Sponsors This Study?

Lead: New York State Psychiatric Institute

Collaborator Sponsor

  • Columbia University
  • University of Southern California
  • Feinstein Institute for Medical Research
  • University of Miami

Source: ID: NCT03900273